Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Submits Humira sBLA for Juvenile Rheumatoid Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, Humira would compete directly with Wyeth/Amgen’s Enbrel in the indication.

You may also be interested in...



Abbott’s Humira Approved For Juvenile Idiopathic Arthritis

Tumor necrosis factor inhibitor an important option to Wyeth’s Enbrel, Abbott tells “The Pink Sheet” DAILY.

Abbott’s Humira Approved For Juvenile Idiopathic Arthritis

Tumor necrosis factor inhibitor an important option to Wyeth’s Enbrel, Abbott tells “The Pink Sheet” DAILY.

Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis

A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel